PTEN and endometrial cancer: Our goal in the present study was to clarify whether PTEN mutations mediated the inhibitory efficiency of PARP-inhibitors (olaparib and BMN-673) through HR functionality, and evaluate whether the Pan-PI3K inhibitor (BKM-120) sensitized endometrial cancer cell lines to PARP inhibitors through HR suppression.